[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580146":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":27,"centralContacts":34,"locations":40,"responsibleParty":76,"collaborators":78,"id":81,"slug":82,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":26,"eligibilityCriteria":87,"healthyVolunteers":83,"sex":88,"minAge":89,"maxAge":26,"enrollmentInfo":90,"targetDuration":26,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":26,"overallStatus":42,"whyStopped":26,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"H. Lee Moffitt Cancer Center and Research Institute","OTHER",[8,13,17],{"label":9,"type":6,"description":10,"interventionNames":11},"Triple negative","Participants diagnosed with triple negative breast cancer.",[12],"Other: CT Scan",{"label":14,"type":6,"description":15,"interventionNames":16},"HER2+","Participants diagnosed with HER2+ breast cancer.",[12],{"label":18,"type":6,"description":19,"interventionNames":20},"Hormone receptor (HR)+","Participants diagnosed with hormone receptor (HR)+ breast cancer.",[12],[22],{"type":6,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"CT Scan","Participants will undergo a screening CT thorax, abdomen, pelvis at baseline prior to adjuvant radiation therapy and additional screening CT thorax, abdomen, and pelvis at 6 months if the baseline CT is found to be negative.",[14,18,9],null,[28,32],{"name":29,"affiliation":30,"role":31},"Kamran Ahmed","Moffitt Cancer Center","PRINCIPAL_INVESTIGATOR",{"name":33,"affiliation":30,"role":31},"Matthew Mills",[35],{"name":36,"role":37,"phone":38,"phoneExt":26,"email":39},"Marian Hernandez","CONTACT","813-745-1807","marian.hernandez@moffitt.org",[41],{"facility":30,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"RECRUITING","Tampa","Florida","33612","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-82.45843,27.94752,{"lat":52,"lon":51},[55,57,59,62,64,66,68,70,72,74],{"name":56,"role":31,"phone":26,"phoneExt":26,"email":26},"Kamran Ahmed, MD",{"name":58,"role":31,"phone":26,"phoneExt":26,"email":26},"Matthew Mills, MD",{"name":60,"role":61,"phone":26,"phoneExt":26,"email":26},"Avan Armaghani, MD","SUB_INVESTIGATOR",{"name":63,"role":61,"phone":26,"phoneExt":26,"email":26},"Ricardo Costa, MD",{"name":65,"role":61,"phone":26,"phoneExt":26,"email":26},"Roberto Diaz, MD, PhD",{"name":67,"role":61,"phone":26,"phoneExt":26,"email":26},"Loretta Loftus, MD",{"name":69,"role":61,"phone":26,"phoneExt":26,"email":26},"Tracey O'Connor, MD",{"name":71,"role":61,"phone":26,"phoneExt":26,"email":26},"Hatem Soliman, MD",{"name":73,"role":61,"phone":26,"phoneExt":26,"email":26},"Aixa Soyano Muller, MD",{"name":75,"role":61,"phone":26,"phoneExt":26,"email":26},"Iman Washington, MD",{"type":77,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[79],{"name":80,"class":6},"Florida Breast Cancer Foundation","100580146","phase-2-phase-ii-study-of-systemic-screening-in-pathologic-node-positive-breast-cancer-100580146",false,"NCT06833502","Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer","Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer Following Neoadjuvant Chemotherapy and Surgery","Inclusion Criteria:\n\n* Histologic diagnosis of breast cancer with documentation of ER\u002FPR\u002FHER2 status.\n* HR+ will be defined as ER and\u002For PR ≥ 10%. To be classified as HER2+ disease, overexpression of HER2 by either IHC or in-situ hybridization is necessary as defined by the ASCO \u002F CAP Guidelines27. Triple negative will be classified as ER and PR \\\u003C10% and HER2-.\n* Node positive HER2+ and triple negative breast cancer (ypN+) following receipt of neoadjuvant chemotherapy. HR+\u002FHER2- patients should have ypN2 or ypN3 disease following receipt of neoadjuvant chemotherapy and surgery.\n* Patient must have completed a minimum of 8 weeks of standard neoadjuvant chemotherapy consisting of an anthracycline and\u002For taxane-based regimen. To include HER2 directed therapy for HER2+ patients.\n* Age ≥ 18.\n* Life expectancy ≥ 6 months.\n* Eastern Cooperative Oncology Group performance status 0 to 2.\n* Patients must be able to understand and the willingness to sign an informed consent for study procedures.\n* Ability to understand and stated willingness to comply with all study procedures and availability for the duration of the study.\n\nExclusion Criteria:\n\n* Prior diagnosis of systemic metastases.\n* Patients with prior history of non-breast cancer malignancies should have NED ≥ 2 years excluding adequately treated non-melanoma skin cancer, in situ cancer of the cervix or bladder.\n* Contraindication towards CT IV contrast.\n* Chronic kidney disease stage IV or V or end stage renal disease (CrCl \\\u003C30 ml\u002Fmin).","ALL","18 Years",{"count":91,"type":92},120,"ESTIMATED","INTERVENTIONAL",[95],"PHASE2","The purpose of the study is to determine the frequency of systemic metastasis in node positive breast cancer following chemotherapy and surgery. Participants will be asked to spend about 6 months in this study. Participants will undergo a computed tomography (CT) screening of the thorax, abdomen, and pelvis at baseline prior to adjuvant radiation therapy and another CT screening of the thorax, abdomen, and pelvis at 6 months if the baseline CT is found to be negative.",[98,99],"Breast Cancer","Node-positive Breast Cancer","2026-06-30",{"date":102,"type":103},"2026-07-02","ACTUAL",{"date":105,"type":103},"2025-02-24",{"date":107,"type":92},"2026-10",{"name":5,"class":6},1]